TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients' ≥ 6 months - 6 years~* Patients must meet criteria for American Society of Anesthesiologists (ASA) physical status I, II.~* Patients must not be pre-medicated.~* Parents must give written consent on the surgery day and be able to sign informed consent form on the surgery day.~* Undergoing BMT surgery only.~Exclusion Criteria:~* Patients' \<6 months and \>6 years.~* Patients with known allergies to any of the medications used in this study.~* Patients with ASA status III \& IV.~* Patients taking prescription pain medications prior to surgery.~* Patients taking medication that can cause drowsiness or alter mental status (eg. benzodiazepines, cough suppressants, diphenhydramine)~* Patients with significant history of psychiatric illness, neurologic disease (seizure disorder requiring medication therapy), and developmental delay.~* Patients have been pre-medicated.~* Patients undergoing other procedures that would prolong anesthetic exposure or confound post-operative pain.~* Intra-op complication that would require prolonged anesthetic exposure.~* If patient took acetaminophen prior to surgery and was not supposed to do so~* Patients that received ketorolac or additional analgesia during surgery.~* Patients that have liver disease.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 6 Years
- Healthy Volunteers: t

Study Arms:
- Acetaminophen PR (Type: ACTIVE_COMPARATOR): Acetaminophen PR (20-40mg/kg) after induction of Anesthesia (acetaminophen is in suppository form and given rectally)
- Acetaminophen PO-low dose (Type: ACTIVE_COMPARATOR): Acetaminophen PO (10mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)
- Acetaminophen PO-high dose (Type: ACTIVE_COMPARATOR): Acetaminophen PO (20mg/kg) 60-120min before start of BMT placement (acetaminophen is in syrup form and given by mouth)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of Rheumatoid Arthritis~1. Patient with a confirmed Rheumatoid Arthritis according the American College of Rheumatology (ACR) classification criteria.~   Disease Activity~2. Patient with a DAS28 greater than 3.2.~   Treatment~3. Patient eligible for a first line TNFα blocking agent treatment with infliximab according to the Summary of Product Characteristics,~4. Patient refractory to treatment with at least one classical DMARDs (one of which has to be MTX) prescribed according to the international recommendations, i.e. for at least 12 weeks at the maximal tolerated dose prior to infliximab treatment and with doses which must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy (patients may be included if they have undergone a wash-out period using cholestyramine or equivalent subsequent to leflunomide treatment),~5. Use of oral steroids (≤ 10mg/day of prednisone or equivalent dose of another molecule) and/or NSAIDs will be permitted; doses must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy,~   Other criteria~6. Patient (male or female) at 18 years of age or older at inclusion,~7. Negative β-HCG pregnancy test, when appropriate according to the patient's age and contraceptive method,~8. Informed consent signed.~Exclusion Criteria:~1. Patient having received previous courses of other biologic therapy (TNF blocking agents, anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in development),~2. Patient non eligible to infliximab therapy according to the Summary of Product Characteristics,~3. Patient with clinically significant, severe and uncontrolled infectious diseases,~4. Patient with symptoms of a significant somatic or psychiatric/mental illness,~5. Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic Lupus Erythematosus, vasculitis, uncontrolled asthma, etc...),~6. Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic, gastro-intestinal conditions, which, in the opinion of the investigator, may interfere with the study,~7. Pregnancy,~8. Patient that is participating in a clinical trial or that participated in a previous one within 10 weeks prior to study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- a single group of patients -200 expected (Type: None): polyarthrite rhumatoid patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* hepatectomy or segmentectomy~Exclusion Criteria:~* Sepsis uncontrolled current~* Overdose in anticoagulant during general anesthesia~* Thrombocytopenia \<50 g / dl~* Severe renal impairment: Cockcroft \<30 ml / min~* history of ventricular arrhythmia serious unexplained .\*~* Allergy to local anesthetics of the amide~* Contraindication to remifentanil and morphine~* Hypovolemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ropivacaïne chlorhydrate monohydrate (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Catheter Thrombectomy in Patients With Massive Pulmonary Embolism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients \>= 18 years of age with pulmonary embolism and cardiogenic shock, defined as a systolic arterial pressure \<= 90 mmHg, a drop in systolic arterial pressure \>= 40 mmHg for \>= 15 minutes, or ongoing administration of catecholamines for systemic arterial hypotension~2. Subtotal or total filling defect in the left and/or right main pulmonary artery due to massive PE, as assessed by chest computed tomography or by conventional pulmonary angiography~3. Right ventricular dysfunction on echocardiography: RV systolic hypokinesis and/or RV dilation (optional)~4. Failed thrombolysis or at least one of the following contraindications to PE thrombolysis present:~   * Active bleeding~  * History of intracranial bleeding~  * Surgery, delivery, organ biopsy, puncture of a non-compressible vessel within 10 days~  * History of stroke~  * Gastrointestinal bleeding within 10 days~  * Significant trauma within 15 days~  * Head injury requiring hospitalization within 1 year~  * Active cancer with known hemorrhagic risk~  * Neurosurgery or ophthalmologic surgery within the past year~  * Platelets \< 50,000 or INR \>2.0~  * Pregnancy~Exclusion Criteria~1. Systemic (paradoxical) embolism in the presence of an atrial septal defect or patent foramen ovale~2. Free floating right heart thrombi, left heart thrombi~3. Life expectancy due to underlying disease less than one month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes of Lumbar Degenerative Disc Disease in Active-Duty U.S. Service Personnel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Degenerative Disc Disease (DDD) in one vertebral level between L3 and S1, where a diagnosis of DDD requires:~   1. Back and/or leg (radicular) pain; and~  2. Radiographic confirmation of any one of the following by CT, MRI, discography, plain film, myelography, and/or flexion/extension films:~   i. Decreased disc height \> 2 mm; ii. Scarring/thickening of annulus fibrosis; iii. Herniated nucleus pulposus; or iv. Vacuum phenomenon.~2. Skeletally mature adult between the ages of 18 and 50 years at time of surgery.~3. Failed at least 6 months of conservative therapy.~4. Oswestry Low Back Pain Disability Questionnaire score ≥ 20/50 (40%) (Interpreted as moderate/severe disability).~5. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.~6. Plans to remain on active duty for a minimum of two (2) years.~7. Personally signed and dated the informed consent document prior to any study-related procures indicating that the subject has been informed of all pertinent aspects of the study.~Exclusion Criteria:~1. More than one vertebral level to be treated.~2. The involved vertebral endplates dimensionally smaller than 34.5 mm in the medial-lateral direction and/or 27 mm in the anterior-posterior direction.~3. Known allergy to polyethylene, cobalt chromium, or molybdenum~4. Prior fusion surgery at any lumbar vertebral level.~5. Clinically compromised vertebral body at the affected level due to current or past trauma.~6. Radiographic confirmation of facet joint disease or degeneration.~7. Lytic spondylolisthesis or spinal stenosis.~8. Degenerative spondylolisthesis \> Grade 1.~9. Osteoporosis: A screening questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis Risk Estimation), will be used to screen patients who require a DEXA bone mineral density measurement. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score \</= -2.5.~10. Known history of Paget's disease, osteomalacia, or any other metabolic bone disease.~11. Morbid obesity defined as a body mass index \> 40 kg/m2 or weight more than 100 pounds over ideal body weight.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- ProDisc L (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: CICERO- A Care Home Study of COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Persons resident or requiring access to the care home~* Capable of giving written informed consent, or if appropriate, having an acceptable individual capable of giving consent on the participant's behalf.~Exclusion Criteria:~* Persons not providing informed consent or withdrawing consent at any time during the study.~* Persons requiring urgent and immediate access to the care home, for example medical staff attending emergency visits.~* Persons unable to provide nasal or oropharyngeal swabs for medical reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: t

Study Arms:
- Standard of care (Type: ACTIVE_COMPARATOR): Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14
- Near Patient Testing (Type: EXPERIMENTAL): Screening for COVID-19 via nasopharyngeal swab taken at day 0 and 14, with the addition of daily nasal swabs tested via rapid test system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Sukhshanti Study: Effect of a Sanitation Intervention on Women's Health

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between 14 years to 65 years old~* live in geographic area receiving GSF sanitation intervention in 2016~* live in geographic areas matched to intervention communities~Exclusion Criteria:~* less than 25 years old and not reached menarche~* greater than 25 years old and never married~* refusal to participate

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- GSF Sanitation intervention (Type: EXPERIMENTAL): This arm will receive the GSF sanitation intervention, a community-level sanitation intervention
- Comparator (Type: NO_INTERVENTION): This arm will receive the GSF intervention in 2017 or later.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 19 years old~* Patients eligible for percutaneous coronary intervention~* Single or more lesion(s) of restenosis requiring angioplasty in drug-eluting stent~* Reference vessel diameter of target lesion ≥2.5 mm~Exclusion Criteria:~* Cardiogenic shock~* Bifurcation lesion or totally occluded lesion~* Unprotected left main trunk lesion~* Allergies or hypersensitivities to antiplatelet, anticoagulation therapy, contrast media, or paclitaxel~* Heavy calcified (definite calcified lesions on angiogram) or extremely tortuous lesions~* Pregnant women or women with potential childbearing~* Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator~* Inability to understand or read the informed content

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pantera Lux (Type: EXPERIMENTAL): None
- SeQuent Please (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: 3-Dimensional Conformal Radiation Therapy or Internal Radiation Therapy After Breast-Conserving Surgery in Treating Women With Stage I or Stage II Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically proven invasive ductal carcinoma of the breast~  * Stage I or II disease (pathological tumor size ≤ 3 cm, N0, M0 disease)~    * No T2 (tumor size \> 3 cm) or T3 disease~   * No lymph node (L0) or hemangiosis (V0) invasion~* Unilateral, unifocal, and unicentric tumor without associated suspicious diffuse microcalcification in the ipsilateral or contralateral breast~  * No multifocal/multicentric disease~* Previously treated with breast-conserving surgery with adequate axillary node management~  * Negative surgical resection margins for tumor (invasive tumor or ductal carcinoma in situ \[DCIS\]) on histology~ * Clearly identified primary tumor excision cavity (clips recommended) with a target lumpectomy cavity/whole breast ratio quantifiable and ≤ 25% on the post-operative CT scan~    * Patients with a lumpectomy cavity/whole breast ratio 25-30% are eligible but will undergo partial breast irradiation using multi-catheter interstitial brachytherapy during study~* Breast size amenable to partial breast irradiation (i.e., \> A-cup size)~* No other pathological invasive tumor or DCIS~* No associated extensive DCIS component (\< 25%)~* No associated Paget's disease of the nipple~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No breast implants~* No collagen vascular disease~* No psychiatric condition or other condition that, in the opinion of the investigator, would preclude study requirements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radiotherapy~* No concurrent chemotherapy~  * Sequential chemotherapy allowed~* Concurrent hormonal therapy allowed

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients undergo accelerated partial breast irradiation (APBI) using 3-dimensional conformal radiation therapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: EXPERIMENTAL): Patients undergo APBI using multi-catheter interstitial brachytherapy twice daily over 5-10 days (total of 10 fractions) in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must be a patient admitted voluntarily to the UMMC adult psychiatric inpatient services with suicidal thoughts / intent / plan or suicide attempt who also has MSRFs including anxiety, agitation, insomnia, and/or depression).~2. Subject must be between the ages of 18 and 65 (inclusive). Both men and women will be included~3. Subjects who are female must have a negative pregnancy test prior to enrolling in the study, and must be practicing at least one or more the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, or oral/hormonal contraception or abstinence, which is typically the case on the inpatient units.~4. If a subject has a substance abuse disorder, they must also have another non-substance abuse psychiatric disorder as determined from the clinical history.~5. Chronic medical conditions such as endocrine disease, hypertension, renal disease, must be stable.~6. Subject must be capable of giving informed consent. Subject must provide written informed consent prior to study participation.~7. Subject must be capable of doing active or sham CES treatments and completing all study requirements.~Exclusion Criteria:~1. Subject has a significant medical disorder with acute symptoms which could impair reliable participation in the trial or affect their MSRFs.~2. Subject is pregnant.~3. Subject has had concomitant therapy with another investigational drug, or participation in an investigational drug study within one month prior to entering this study.~4. Subject has a clinical history of poor compliance or in the investigator's judgment participation in the study would be clinically contraindicated.~5. Subject has current or past behavior that suggests to the investigator that his/her suicidal behavior is driven by secondary gain, i.e. expressing suicidal thoughts so that s/he can be admitted due to homelessness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Adjunctive CES (Type: EXPERIMENTAL): CES 100µA for one hour daily, five to seven days per week. Rating scales will be administered at baseline (i.e., pre-treatment), twice a week and at the end of the study.
- Sham control CES (Type: SHAM_COMPARATOR): For the sham group the Alpha-Stim® will not emit electricity. All other procedures will be the same for both the sham group and the active CES group. The current intensity will be preset and locked by the manufacturer. The sham devices will appear identical to the active device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility